High-dose tenofovir is not effective in suppressing hepatitis B virus replication in patients with hepatocellular carcinoma progression: a preliminary result.
10.14701/kjhbps.2016.20.1.8
- Author:
Shin HWANG
1
;
Gi Won SONG
;
Dong Hwan JUNG
;
Young In YOON
;
Hyun Ju YOO
;
Eunyoung TAK
Author Information
1. Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. shwang@amc.seoul.kr
- Publication Type:Original Article
- Keywords:
Nucleoside analogues;
Entecavir;
Covalently closed circular DNA;
HBV X protein;
Recurrence
- MeSH:
Carcinoma, Hepatocellular*;
DNA;
Follow-Up Studies;
Hepatitis B virus*;
Hepatitis B*;
Hepatitis*;
Humans;
Male;
Prospective Studies;
Recurrence;
Sleep Initiation and Maintenance Disorders;
Tablets;
Tenofovir
- From:Korean Journal of Hepato-Biliary-Pancreatic Surgery
2016;20(1):8-11
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUNDS/AIMS: Nucleos(t)ide analogues (NUCs) effectively suppress hepatitis B virus (HBV) replication, but hepatocellular carcinoma (HCC) recurrence often leads to HBV replication despite NUC therapy. The aim of this study was to determine whether high-dose tenofovir (TNF) therapy can suppresses HCC recurrence-associated HBV replication. METHODS: We performed a single-arm prospective study to assess the clinical feasibility of high-dose TNF (hdTNF). We recruited 10 patients during September 2015 and followed up for 3 months or early drop-out. RESULTS: All 10 patients had HCC of advanced stages due to HCC recurrence and gradual progression. The average age of patients was 51.2+/-4.7 years and 9 were male. Three patients did not tolerate the increased TNF dosage and were dropped out early. The other 7 patients were relatively tolerable to the increased dosage of TNF 5 tablets per day. One patient had mild gastrointestinal symptoms and another patient complained of insomnia. Increased HBV replication and HCC progression was observed despite hdTNF for 4-8 weeks. All 7 patients showed tumor progression during the 3 month follow-up. In these patients, blood HBV DNA before hdTNF was 50-200 copies/ml; and 4-8 weeks after hdTNF, the HBV replication status was not improved with blood HBV DNA of 50-300 copies/ml. This clinical study was terminated early after these negative results were confirmed. CONCLUSIONS: The results of this study indicated that high dose of TNF up to 5-fold the recommended dosage is not tolerated by a considerable proportion of patients and also ineffective in suppressing HCC progression-associated HBV replication.
